Professor | Zhigang Liu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Zhigang Liu
Contact Information	zhigang.liu@zju.edu.cn
Language ability	English, Chinese
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Zhigang Liu

Contact Information

zhigang.liu@zju.edu.cn

Language ability

English, Chinese

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Medical
Academic Background & Achievements	2006-2011 Bachelor of Medicine: Huazhong University of Science and Technology 2011-2016 PhD in Analytical Chemistry: University of Chinese Academy of Sciences Published over 50 papers in high-impact journals Applied for 1 international patent and 2 Chinese patents
Work Experience	2017-2024 - Imperial College London - Research Associate 2024- - Zhejiang University - Hundred Talents Program Researcher, Doctoral Supervisor 2024- - Imperial College London - Visiting Professor
Awards	Best IBD Oral Presentation Award (2022): British Society of Gastroenterology, Birmingham, UK Best Oral Presentation (2019): 25th CLSS-UK Annual Conference, London, UK Outstanding Poster Award (2016): 7th International Symposium on Bioanalysis, Biomedical Engineering & Nanotechnology, Changsha, China Outstanding Poster Award (2015): 6th Asia-Pacific NMR Symposium, Hong Kong

University/Lab Affiliation and Title

Zhejiang University

Faculty

Medical

Academic Background & Achievements

2006-2011 Bachelor of Medicine: Huazhong University of Science and Technology
2011-2016 PhD in Analytical Chemistry: University of Chinese Academy of Sciences
Published over 50 papers in high-impact journals
Applied for 1 international patent and 2 Chinese patents

Work Experience

2017-2024 - Imperial College London - Research Associate
2024- - Zhejiang University - Hundred Talents Program Researcher, Doctoral Supervisor
2024- - Imperial College London - Visiting Professor

Awards

Best IBD Oral Presentation Award (2022): British Society of Gastroenterology, Birmingham, UK
Best Oral Presentation (2019): 25th CLSS-UK Annual Conference, London, UK
Outstanding Poster Award (2016): 7th International Symposium on Bioanalysis, Biomedical Engineering & Nanotechnology, Changsha, China
Outstanding Poster Award (2015): 6th Asia-Pacific NMR Symposium, Hong Kong

Areas of Focus	Interaction mechanisms between gut microbiota and inflammatory bowel disease Epidemiology and big data analysis of inflammatory bowel disease Target research and new drug development for inflammatory bowel disease
Publications	Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with inflammatory bowel disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study (CLARITY), Liu Z, Le K, Zhou X, Alexander J, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald T, Lamb C, Sebastian S, Kok K, Lees C, Hart A, Pollok R, Boyton R, Altmann DM, Pollock KM, Goodhand J, Kennedy N, Ahmad T, Powell N., 2023 Infliximab and tofacitinib attenuate neutralising antibody responses against SARS-CoV-2 ancestral and Omicron variants in IBD patients following 3 doses of COVID-19 vaccine, Liu Z, Alexander J, Lin K, Ahmad T, Pollock K, Powell N., 2023 Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study, Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin K, McFarlane L, Constable L, Castro Seoane R, Anand N, Bewshea C, Nice R, D'Mello A, Jones G, Balarajah S, Fiorentino F, Sebastian S, Irving P, Hicks L, Williams H, Kent A, Linger R, Parkes M, Kok K, Patel K, Teare J, Altmann D, Boyton R, Hart A, Lees C, Goodhand J, Kennedy N, Pollock K, Ahmad T, Powell N., 2023 Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib, Liu Z, Alexander J, Eng K, Ibraheim H, Anandabaskaran S, Saifuddin A, Constable L, Castro Seoane R, Bewshea C, Nice R, D'Mello A, Jones G, Balarajah S, Fiorentino F, Sebastian S, Irving P, Hicks L, Williams H, Kent A, Linger R, Parkes M, Kok K, Patel K, Teare J, Altmann D, Boyton R, Hart A, Lees C, Goodhand J, Kennedy N, Pollock K, Ahmad T, Powell N., 2023 Systemic metabolic profiling and gene expression in a microbiota-dependent model of ulcerative colitis, Liu Z, Le K, Powell N., 2023 Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type strain in patients with IBD after three doses of COVID-19 vaccine, Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Constable L, Bewshea C, Jones G, Sebastian S, Irving P, Hart A, Lees C, Boyton R, Goodhand J, Kennedy N, Pollock K, Ahmad T, Powell N., 2023 Deciphering the transcriptomic and metabolic alterations in a microbiota-dependent model of ulcerative colitis, Liu Z, Le K, Powell N., 2023 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy, Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin K, Mcfarlane L, Anand N, Constable L, Castro-Seoane R, Nice R, Bewshea C, D'Mello A, Jones G, Balarajah S, Fiorentino F, Sebastian S, Irving P, Hicks L, Williams H, Kent A, Linger R, Parkes M, Kok K, Patel K, Teare J, Altmann D, Hart A, Lees C, Boyton R, Goodhand J, Kennedy N, Pollock K, Ahmad T, Powell N., 2023 The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients, Alexander J, Mullish B, Danckert N, Liu Z, Olbei M, Saifuddin A, Torkizadeh M, Ibraheim H, Miguéns J, Roberts L, Bewshea C, Nice R, Lin S, Prabhudev H, Sands C, Horneffer V, Lewis M, Sebastian S, Lees C, Teare J, Hart A, Goodhand J, Kennedy N, Korcsmaros T, Marchesi J, Ahmad T, Powell N., 2023 Vitamin D concentrations are not associated with anti-SARS-CoV-2 antibody responses following mRNA COVID-19 vaccine in IBD patients treated with infliximab, Smith R, Liu Z, Laskey K, Lin S, Chanchlani N, Nice R, Roberts C, Alexander J, McDonald T, Bewshea C, Kennedy N, Goodhand J, Powell N, Ahmad T, The CLARITY IBD Study Group., 2023 Vaccine-induced antibody responses against influenza are diminished in infliximab and tofacitinib-treated IBD patients and correlate with responses to COVID-19 vaccination, Alexander J, Liu Z, Eng K, Ibraheim H, Saifuddin A, Bewshea C, Balarajah S, Sebastian S, Irving P, Hicks L, Kent A, Parkes M, Kok K, Patel K, Hart A, Lees C, Goodhand J, Kennedy N, Ahmad T, Powell N., 2023 Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis, Lo J, Cozzetto D, Alexander J, Danckert N, Madgwick M, Knox N, Sieh J, Olbei M, Liu Z, Ibraheim H, Blanco J, Kudo H, Seoane R, Possamai L, Goldin R, Marchesi J, Korcsmaros T, Lord G, Powell N., 2023

Areas of Focus

Interaction mechanisms between gut microbiota and inflammatory bowel disease
Epidemiology and big data analysis of inflammatory bowel disease
Target research and new drug development for inflammatory bowel disease

Publications

Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with inflammatory bowel disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study (CLARITY), Liu Z, Le K, Zhou X, Alexander J, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald T, Lamb C, Sebastian S, Kok K, Lees C, Hart A, Pollok R, Boyton R, Altmann DM, Pollock KM, Goodhand J, Kennedy N, Ahmad T, Powell N., 2023
Infliximab and tofacitinib attenuate neutralising antibody responses against SARS-CoV-2 ancestral and Omicron variants in IBD patients following 3 doses of COVID-19 vaccine, Liu Z, Alexander J, Lin K, Ahmad T, Pollock K, Powell N., 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study, Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin K, McFarlane L, Constable L, Castro Seoane R, Anand N, Bewshea C, Nice R, D'Mello A, Jones G, Balarajah S, Fiorentino F, Sebastian S, Irving P, Hicks L, Williams H, Kent A, Linger R, Parkes M, Kok K, Patel K, Teare J, Altmann D, Boyton R, Hart A, Lees C, Goodhand J, Kennedy N, Pollock K, Ahmad T, Powell N., 2023
Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib, Liu Z, Alexander J, Eng K, Ibraheim H, Anandabaskaran S, Saifuddin A, Constable L, Castro Seoane R, Bewshea C, Nice R, D'Mello A, Jones G, Balarajah S, Fiorentino F, Sebastian S, Irving P, Hicks L, Williams H, Kent A, Linger R, Parkes M, Kok K, Patel K, Teare J, Altmann D, Boyton R, Hart A, Lees C, Goodhand J, Kennedy N, Pollock K, Ahmad T, Powell N., 2023
Systemic metabolic profiling and gene expression in a microbiota-dependent model of ulcerative colitis, Liu Z, Le K, Powell N., 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type strain in patients with IBD after three doses of COVID-19 vaccine, Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Constable L, Bewshea C, Jones G, Sebastian S, Irving P, Hart A, Lees C, Boyton R, Goodhand J, Kennedy N, Pollock K, Ahmad T, Powell N., 2023
Deciphering the transcriptomic and metabolic alterations in a microbiota-dependent model of ulcerative colitis, Liu Z, Le K, Powell N., 2023
COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy, Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin K, Mcfarlane L, Anand N, Constable L, Castro-Seoane R, Nice R, Bewshea C, D'Mello A, Jones G, Balarajah S, Fiorentino F, Sebastian S, Irving P, Hicks L, Williams H, Kent A, Linger R, Parkes M, Kok K, Patel K, Teare J, Altmann D, Hart A, Lees C, Boyton R, Goodhand J, Kennedy N, Pollock K, Ahmad T, Powell N., 2023
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients, Alexander J, Mullish B, Danckert N, Liu Z, Olbei M, Saifuddin A, Torkizadeh M, Ibraheim H, Miguéns J, Roberts L, Bewshea C, Nice R, Lin S, Prabhudev H, Sands C, Horneffer V, Lewis M, Sebastian S, Lees C, Teare J, Hart A, Goodhand J, Kennedy N, Korcsmaros T, Marchesi J, Ahmad T, Powell N., 2023
Vitamin D concentrations are not associated with anti-SARS-CoV-2 antibody responses following mRNA COVID-19 vaccine in IBD patients treated with infliximab, Smith R, Liu Z, Laskey K, Lin S, Chanchlani N, Nice R, Roberts C, Alexander J, McDonald T, Bewshea C, Kennedy N, Goodhand J, Powell N, Ahmad T, The CLARITY IBD Study Group., 2023
Vaccine-induced antibody responses against influenza are diminished in infliximab and tofacitinib-treated IBD patients and correlate with responses to COVID-19 vaccination, Alexander J, Liu Z, Eng K, Ibraheim H, Saifuddin A, Bewshea C, Balarajah S, Sebastian S, Irving P, Hicks L, Kent A, Parkes M, Kok K, Patel K, Hart A, Lees C, Goodhand J, Kennedy N, Ahmad T, Powell N., 2023
Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis, Lo J, Cozzetto D, Alexander J, Danckert N, Madgwick M, Knox N, Sieh J, Olbei M, Liu Z, Ibraheim H, Blanco J, Kudo H, Seoane R, Possamai L, Goldin R, Marchesi J, Korcsmaros T, Lord G, Powell N., 2023

Gut Microbiota Inflammatory Bowel Disease Interaction Mechanisms Epidemiology Big Data Analysis Target Research New Drug Development Metabolomics Transcriptomics Bioinformatics

Ning Shen - Zhejiang University

Yan Ni - Zhejiang University

Xushen Xiong - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us